The use of prostate-specific membrane antigen (PSMA) PET imaging has greatly improved our ability to identify oligometastases in prostate cancer and should routinely be used in evaluating patients with potentially recurrent disease. The gene discussed is FOLH1; the disease is prostate carcinoma.